Oliceridine: First Approval

Drugs. 2020 Nov;80(16):1739-1744. doi: 10.1007/s40265-020-01414-9.

Abstract

Oliceridine (Olinvyk™, Trevena, Inc.) is a novel μ opioid agonist that was recently approved in the USA for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Unlike opioid agonists currently in use, the interaction of oliceridine with the opioid receptor is selective to the G protein pathway, with low potency for β-arrestin recruitment, which may lead to fewer opioid-related adverse events. This article summarizes the milestones in the development of oliceridine leading to this first approval.

Publication types

  • Review

MeSH terms

  • Acute Pain / diagnosis
  • Acute Pain / drug therapy*
  • Administration, Intravenous
  • Adult
  • Analgesia, Patient-Controlled / adverse effects
  • Analgesia, Patient-Controlled / methods
  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / pharmacokinetics
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Dose-Response Relationship, Drug
  • Drug Approval*
  • Humans
  • Pain Measurement
  • Receptors, Opioid, mu / agonists
  • Severity of Illness Index
  • Spiro Compounds / administration & dosage*
  • Spiro Compounds / adverse effects
  • Spiro Compounds / pharmacokinetics
  • Thiophenes / administration & dosage*
  • Thiophenes / adverse effects
  • Thiophenes / pharmacokinetics

Substances

  • ((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
  • Analgesics, Opioid
  • Receptors, Opioid, mu
  • Spiro Compounds
  • Thiophenes